Financials in USD. Standardized financial statements.
A compact view of how SQZ Biotechnologies Company turns revenue into operating income and net income.
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|
| Revenue? | $21.03M | $27.10M | $21.00M | $20.11M | $12.67M |
| Revenue Growth? | -22.4% | +29.1% | +4.4% | +58.7% | 0.0% |
| Cost of Revenue? | $11.68M | $11.03M | $0 | $0 | $0 |
| Gross Profit? | $9.79M | $16.07M | $21.00M | $20.11M | $12.67M |
| Gross Margin? | +46.6% | +59.3% | +100.0% | +100.0% | +100.0% |
| Operating Expenses? | $85.62M | $84.84M | $72.06M | $50.02M | $32.01M |
| Operating Income? | -$80.68M | -$68.77M | -$51.06M | -$34.27M | -$20.40M |
| EBITDA? | -$64.14M | -$57.74M | -$40.12M | -$29.91M | -$18.18M |
| Income Before Tax | -$79.46M | -$68.74M | -$50.52M | -$32.20M | -$19.25M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $984,000 |
| Net Income? | -$79.46M | -$68.74M | -$50.52M | -$32.20M | -$20.23M |
| EPS? | $-2.76 | $-2.49 | $-2.04 | $-1.31 | $-0.82 |
| Diluted EPS? | $-2.76 | $-2.49 | $-2.04 | $-1.31 | $-0.82 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality